In Silico Study and Preclinical Evaluation of Radioiodinated Procaterol as a Potential Scintigraphic Agent for Lung Imaging
Sanad, M., Saleh, G., Tallat, H. (2017). In Silico Study and Preclinical Evaluation of Radioiodinated Procaterol as a Potential Scintigraphic Agent for Lung Imaging. EKB Journal Management System, 30(2), 117-130. doi: 10.21608/ejrsa.2017.1500.1016
Mahmoud Sanad; Gehan Saleh; Hanan Tallat. "In Silico Study and Preclinical Evaluation of Radioiodinated Procaterol as a Potential Scintigraphic Agent for Lung Imaging". EKB Journal Management System, 30, 2, 2017, 117-130. doi: 10.21608/ejrsa.2017.1500.1016
Sanad, M., Saleh, G., Tallat, H. (2017). 'In Silico Study and Preclinical Evaluation of Radioiodinated Procaterol as a Potential Scintigraphic Agent for Lung Imaging', EKB Journal Management System, 30(2), pp. 117-130. doi: 10.21608/ejrsa.2017.1500.1016
Sanad, M., Saleh, G., Tallat, H. In Silico Study and Preclinical Evaluation of Radioiodinated Procaterol as a Potential Scintigraphic Agent for Lung Imaging. EKB Journal Management System, 2017; 30(2): 117-130. doi: 10.21608/ejrsa.2017.1500.1016

In Silico Study and Preclinical Evaluation of Radioiodinated Procaterol as a Potential Scintigraphic Agent for Lung Imaging

Egyptian Journal of Radiation Sciences and Applications
Article 2, Volume 30, Issue 2, December 2017, Page 117-130  XML PDF (1.22 MB)
Document Type: Original Article
DOI: 10.21608/ejrsa.2017.1500.1016
View on SCiNiTO View on SCiNiTO
Authors
Mahmoud Sanad email 1; Gehan Saleh2; Hanan Tallat3
1Labeled Compounds Department, Radioisotopes Production and Radioactive Sources Division, Hot Laboratories Center, Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt.
2Health Radiation Research department (Radiodiagnosis Unit), National Center for Radiation Research and Technology, Atomic Energy Authority, Cairo, Egypt.
3Labeled Compounds Department, Radioisotopes Production and Radioactive Sources Division, Hot Laboratories Center, Atomic Energy Authority, P.O. Box 13759, Cairo-Egypt.
Abstract
PROCATEROL has been labeled using [125/131I] with chloramine-T (Ch-T) as oxidizing agent which can be used for lung imaging instead of the commercially available complex (Macro-aggregated albumin complex,99mTc-MAA) which is called blood-derived product. In addition, a comparison between a new radiotracer and other radiotracers such as 99mTc-DHPM,99mTc(CO)5I , 125/123I-IPMPD, 125I-fenoterol ,125I-reproterol, 125I-levalbuterol, 99mTc-levosalbutamol and 99mTc-tricarbonyl levosalbutamol is conducted. Factors such as the amount of oxidizing agent(100 μg), amount of substrate (100 μg), pH of reaction mixture (4), ambient temperature and reaction time (15min), have been systematically studied to optimize the iodination. Additionally, the in-vitro stability of radioiodinated procaterol was studied in two different media , namely, saline and serum up to 72 hours that indicates its stability upto 12hr. The labeled compound was separated and purified using thin layer chromatography (TLC), paper electrophoreses and high performance liquid chromatography (HPLC). Biodistribution studies indicated the suitability of radioiodinated procaterol as a novel tracer for lungs imaging. Radioiodinated procaterol could be considered a new radiotracer for lung imaging.
Keywords
Radioiodinated procaterol; Chloramine-T; β2-Adrenoceptor; Molecular Modeling and Gamma scintigraphy
Statistics
Article View: 361
PDF Download: 354